Eight Departments: By 2030, a preliminary collaborative system for the entire traditional Chinese medicine industry chain will be established.

Securities Times Reporter Han Zhongnan

On February 5, the Ministry of Industry and Information Technology, the State-owned Assets Supervision and Administration Commission, the Financial Regulatory Administration, and other eight departments jointly issued the “Implementation Plan for the High-Quality Development of Traditional Chinese Medicine Industry (2026-2030)” (hereinafter referred to as the “Plan”), which clarifies the development goals, key tasks, and guarantee measures for the traditional Chinese medicine industry over the next five years, fully promoting the collaborative upgrade of the entire industry chain of traditional Chinese medicine.

The “Plan” defines the core development goals for 2030 and outlines the path for the high-quality development of the traditional Chinese medicine industry. By then, a collaborative development system for the entire industry chain of traditional Chinese medicine will be initially formed, with a continuous enhancement of the supply capacity of key traditional Chinese medicine raw materials and significant improvements in digital intelligence and sustainability.

Specifically, by 2030, 60 high-standard production bases for traditional Chinese medicine raw materials will be cultivated, 5 innovation centers for traditional Chinese medicine industry will be established, a batch of innovative traditional Chinese medicine drugs will be approved for market launch, 10 major varieties of traditional Chinese medicine will be newly cultivated, 10 industry standards related to digital intelligence technology in traditional Chinese medicine manufacturing will be revised or formulated, 20 typical cases of digital transformation and upgrading will be published, 20 smart factories will be built, and 10 green factories will be cultivated.

To ensure the achievement of these goals, the “Plan” deploys six key actions and 15 specific tasks, focusing on precise efforts at various stages of the industry chain. In terms of raw material security, actions will be implemented to improve quality and stabilize supply, guiding leading enterprises to build high-standard production bases for traditional Chinese medicine raw materials in major production areas, supporting the construction of primary processing factories at production sites, promoting automated production lines and “shared workshops,” while also accelerating the revision of quality standards for medicinal materials and conducting research on the protection of rare medicinal material resources and substitutes.

Innovation is the core driving force for industrial upgrading. The “Plan” proposes to implement a collaborative innovation action, integrating innovation resources from enterprises, universities, and research institutions, building innovation centers for the traditional Chinese medicine industry, and creating a cooperative model among “renowned doctors, renowned hospitals, renowned schools, and renowned enterprises.” At the same time, technologies such as artificial intelligence and big data will be used to empower the research and development of new traditional Chinese medicine drugs, breaking through technological bottlenecks in efficacy component identification and formulation optimization, encouraging innovation and improvement of already marketed traditional Chinese medicine products, promoting the transformation of traditional Chinese medicine preparations in medical institutions into innovative drugs, and cultivating new productive forces in the industry.

In terms of enhancing manufacturing capabilities, the “Plan” clarifies the push for centralized production of traditional Chinese medicine pieces, improving the quality standard system, while accelerating the digital and green transformation of traditional Chinese medicine manufacturing, optimizing the quality traceability system for all processes, and achieving traceability of the source of traditional Chinese medicine products, process monitoring, and verifiability of their destination. Regarding the development of ethnic medicine, an action plan for the revitalization of the ethnic medicine industry will be implemented, exploiting the advantages of ethnic medicine resources, improving the quality control system, promoting the modernization transformation of the ethnic medicine industry, and cultivating renowned ethnic medicine products.

In addition, the “Plan” also deploys actions for the promotion of renowned traditional Chinese medicine products and the cultivation of outstanding enterprises, through strengthening brand protection, cultivating advantageous single products in traditional Chinese medicine and medicinal pieces, promoting cross-border integration of “traditional Chinese medicine +”, and developing health products; gradually cultivating leading enterprises and high-quality small and medium-sized enterprises, supporting enterprises to explore international markets, participating in the formulation and revision of international standards for traditional Chinese medicine, and enhancing the international influence of traditional Chinese medicine brands.

(责任编辑：王治强 HF013)

【Disclaimer】This article only represents the author’s personal views and is not related to Hexun.com. Hexun.com maintains neutrality regarding the statements and opinions contained in this article and does not provide any express or implied guarantee regarding the accuracy, reliability, or completeness of the content. Readers are advised to reference at their own discretion and assume full responsibility. Email: news_center@staff.hexun.com